

Seroprevalence of Brucella Infection among Pregnant Women in Sana'a City, Yemen

Abstract

Introduction: Brucellosis is a leading cause of zoonosis worldwide caused by the bacterial genus. Brucella that transmitted to humans via either, direct or indirect contact with infected animals or their products. Yemeni pregnant women are not routinely tested for Brucellosis. There is no published data concerning brucella seroprevalence during pregnancy. Therefore the aims of our study were to determine the seroprevalence associated risk factors of brucella infection among pregnant women in Sana'a city, Yemen.

Materials and methods: A descriptive cross-sectional study was carried out in some hospitals and clinical health centers in Sana'a city, Yemen from June to August 2016 in order to assess the seroprevalence of brucella IgM and IgG antibodies to brucella among pregnant women by using enzyme-linked immunosorbent assay (ELISA) kits. The serum sample was collected from 304 pregnant women who attended the antenatal clinic in some hospitals and health centers in Sana'a city. Before collection of sample, questionnaires were revolved to the pregnant women to obtain data on socio-demographics, obstetric characteristic, risk factors and clinical symptoms associated with brucella infection.

Results: Of the 304 pregnant women, 42 (13.82%) and 17 (5.95%) were positive for anti-brucella IgM and IgG antibodies, respectively. Urban erea observed significance with anti-brucella IgM seropositive antibodies and also a significant association was found with headache (IgG, P=0.01) and undulant fever (IgM, P=0.02) for brucella IgG and IgM antibodies respectively. All of the possible risk factors studied and reproductive characteristics were not significantly associated with infection (P-value>0.05).

Conclusion: The overall seroprevalence of brucella antibodies was high. This is suggest¬ing that a sustained infection in the Yemeni population and indicating endemicity. Adoption of brucella screening into the antenatal profile tests is recommended. Advance study intended to compare all provinces in the country for brucella seroprevalence in order to get a comprehensive information of the problem is recommended.

Keywords: Seroprevalence; Brucella; Risk factors Pregnant women; ELISA; Sana'a; Yemen

Introduction

Brucellosis, commonly known as "undulant fever", "Mediterranean fever" or "Malta fever" is a leading cause of zoonosis worldwide caused by the bacterial genus brucella [1]. Brucella is an aerobic, gram-negative, non-fermenting, facultative intracellular, non-motile, non-spore-forming, cocci, cocobacilli or short rods based on DNA homology and represent a single species [2,3]. It is transmitted to humans by direct or indirect contact with infected animals or their products [1-5]. The entry of the organism is the conjunctiva, respiratory mucosa and damaged skin [6]. Generally the transmission from person to person is uncommon, however the human sources of infection may occur in the following ways: vertical transmission with placental circulation, breast feeding, sexual contact, blood transfusion and bone marrow transplantation [7]. The most common reported symptoms and signs were fever, headaches, fatigue, malaise, chills, sweats, myalgia, lack of appetite, weight loss and arthralgia [8-11]. The first reported brucellosis during pregnancy was in 1908 when (Malta fever), brucellosis, was clinically described [12]. Lately, spontaneous abortions in women might be associated with the isolation of brucella from an aborted fetuses placenta [13,14]. It is believed that brucellosis causes fewer spontaneous abortions in humans than it does in animals because of the absence of erythritol in the human placenta and fetus [15]. Erythritol is a constituent of normal ungulate fetal and placental tissue and, in cases of bovine abortion, promotes overwhelming infection of the fetus and placenta. Additionally, the reason for the lesser role of abortion in human brucellosis is the presence of anti-brucella activity in human amniotic fluid [13].

Research Article

Volume 1 Issue 1 - 2017

Qais Y M Abdullah, Salwa H Alkhyat, Anas A Almahbashi, Mofeed Al-Nowihi, Assem Al-Thobahni, Mohammed N Q Al-Bana and Saad Al-Arnoot*

Department of Biology, Sana'a University, Yemen

*Corresponding author: Saad Al-Arnoot, Microbiology Branch, Department of Biology, Faculty of Science, Sana'a University, Sana'a, Yemen, Tel: 00967774667900; Email: saad.alarnoot@gmail.com

Received: July 27, 2017 | Published: September 01, 2017

Brucellosis is an endemic disease in the south and central Asia, Middle East, north and east Africa, Mediterranean countries of Europe, and South America. The reported incidence of human brucellosis in endemic disease areas varies widely, from <0.01 to >200 per 100,000 population [4]. Nevertheless, in most countries the incidence of human brucellosis is unknown and it has been estimated that the incidence may be 25 times higher than the reported incidence due to under-reporting or misdiagnosis [16]. In Yemen the seroprevalence of human brucellosis was ranging from 0.3 to 32.3% [17] which remains a major endemic health problem, but there is no published data concerning brucella seroprevalence during pregnancy. So, the aim of this present study was to determine associated risk factors and the prevalence of human brucellosis among pregnant women in Sana'a city, Yemen. It should be performed to contribute in establishing primary database of brucella incidence and prevalence in Yemen. This basic data concerning brucella infection in pregnancy is significant for health planners and care providers.

Materials and Methods

Study area

This study was conducted in Sana'a city. It is the capital of Yemen, located on northern part of the country. It is considered as the largest city in Yemen in terms of population according to the last population enumeration in 2004 which is 1,7476,834 (940585 males, 766728 females and 93157 children below 15 years old), but the number of population might be increased because of emigration to Sana'a as a result of civil war. Six main hospitals and health centers in Sana'a city were chosen as sample collection centers.

Study population and study design

A descriptive cross-sectional study was conducted among 304 pregnant women attending antenatal clinic in some hospitals and health centers in Sana'a city, Yemen during the period between June to August 2016. Inclusion criteria for enrollment in the study were:

- 1) Pregnant women
- 2) Residing in Sana'a city
- 3) Aged 15 years and older and
- 4) Who accepted to participate in the study

Calculation of the sample size was performed with the aid of the Epi Info version 7 software, we used a value of 766728 as a population size from which the sample was selected, a reference seroprevalence of 24.40% [18] as expected frequency of the factor under study, 5% of confidence limits, a design effect of 1.0, one cluster, and a confidence level of 95%. The result of the calculation was 283 subjects.

Data collection

The questionnaire were designed to collect information regarding socio-demographics, reproductive and obstetrical

characteristics, clinical symptoms, and risk related data. It was designed according to many previous studies [19-21] with slight modification to suit this study. The questionnaire was first developed in English and translated into Arabic language in order to be easy for investigators who helped to fill it in some cases. Most of the questions were "Yes or No" type and took about 5 minutes to complete the questionnaire.

Sample collection, handling and storage: After getting oral and written informed consent from the participants, about (Fiveml) blood sample was collected from each consenting subject by venipuncture, transferred into anticoagulant-free sterile bottle, and allowed to clot. Then centrifuged (3000 rpm, 5 min), and the serum was transferred into cryovials. The serum sampled from every subject participating in the study were placed in two separate eppendrof tubes. One was referred to as the original sample and the second was referred to as the backup sample. This was done to avoid repeated freezing/thawing cycles (which were kept to a minimum) or an insufficient quantity of serum. The second sample was used as a backup sample in case anything went wrong with the original one or its quantity was insufficient. Serum samples were stored at -10 to -20 ° C. These samples were stored in different freezers placed in two different locations that both had a backup electricity supply in case there were any power failures and were checked every day, once in the morning and once at night. Twenty-four hours prior to performing the first serological assay, samples were taken out of the freezer and placed in a refrigerator at 4°C overnight. After samples were allowed to thaw in a refrigerator overnight they were removed from the refrigerator early in the morning for performing the serological assay.

Serologic testing

The serum samples were analyzed for Brucella IgG and IgM by using enzyme-linked immunosorbent assay commercial diagnostic kits (Nova Tec Immundiagnostica GmbH, Germany). These assays were used according to the manufacturer's instructions. The reading of these results which obtained in this study were read by a microplate reader (Mindray MR-96A; Shenghen Mindray Bio Medical Electronics Com Ltd, Germany) and compared in a parallel manner with the calibrator and controls. All samples that were equal to or higher than index of 10 were interpreted as positive. The whole samples with an index of 9–10 were equivocal. The controls and the calibrators passed the validation check recommended by the manufacturer of the kit.

Ethical consideration

The ethical of this research was granted by Biology Department, Faculty of Sciences, Sana'a University ethical committee after due process had been followed. Before, the collection of sample, questionnaire of this study was explained to the all women. Confidentiality was assured by using numbers instead of names. Moreover, oral and written consent for participation in the study was obtained.

Statistical Analysis

The data entered and analysis were by using SPSS version 21, and reduced to percentiles and figures. The Pearson χ^2 test at a 95% confidence interval and a significance level of 0.05 was used to determine the relationships between the data collection and seroprevalence rates. *P* values of 0.05 or less was considered to be significant.

Results

About 304 subjects were enrolled in the study which range from 15 to 40 years old with mean age of pregnant women was 25.25 (SD=4.98) years. Out of 304 subject 179 were < 25 years old, while 121 of them were illiterate or have basic education. Most of the subjects, 292 (96.05%) lived in urban area and all almost of them were housewife. Our results showed that the seroprevalence of 5.95% (17 of 304) and 13.82% (42 of 304) for brucella IgG and IgM antibodies, respectively, among pregnant women. Of the 42 (13.81%) pregnant women were positive for brucella IgG antibody, 14 (4.6%) were also positive for brucellaspecific IgG antibody while out of the remaining 28 (9.21%) pregnant women that were positive for brucella IgM antibody, 3 (0.98%) were positive for brucella IgG antibody and the remaining 259 (85.19%) were negative for both IgM and IgG antibodies.

Among the socio demographic variables, only residence of

urban erea observed a significant association with anti- brucella IgM seropositive antibody, however other variables like age, education level and occupation were not associated (Table 1). The most common reproductive characteristics, such as the parity, trimester, preterm delivery, cesarean sections, spontaneous abortions, stillbirths, and malformed children were studied (Table 2). Nearly half of the subject (44.41%) were in their first trimester. 26 (8.55%) of the subjects have more than four children, 16 (5.26%), 99(32.57%), 24 (7.89%), 28 (9.21%) and 6(1.97%) of the pregnant women had a history of abortion, cesarean sections, stillbirth, and malformed children, respectively.

More than half of the subject had anorexia, pain muscles, pain back, coldness, headache, fatigue and cold. Out of this pregnant women, 140 (46.05%), 130 (42.76%), 120 (39.47%), 131 (43.09%), 85 (27.96%) and 38 (12.5%) had fever, undulant fiver, weight loss, pain head back, sweaty and delirium, respectively, at the period of study. There were significant association with headache and undulant fever and the seropositivity for brucella IgG and IgM antibodies respectively (Table 4). Being brucellosis is zoonotic disease, situations that involve or result in contact with infected animals were considered to be as possible risk factors in this study (for example, occupation type, place of residence and polygamy) (Table 3). All the possible risk factors in this study were not significant (*P*-value >0.05).

Table 1: Seroprevalence of brucella IgM and IgG antibodies among pregnant women according to socio-demographical characteristics.

Category	Participants	IgG Positive		IgM Positive	
category	No. (%)	No. (%)	P- Value	No. (%)	P- Value
		Age			
15-25	179(58.88)	10(5.59)		22(12.29)	0.16
26-35	113(37.17)	6(5.31)	0.91	20(17.70)	
36-45	12(3.95)	1 (8,38)		0(0.00)	
		Residence			
Rural	91 (29.93)	3(3.30)	0.25	7(7.69)	0.04*
Urban	213 (70.07)	14(6.57)		35(16.43)	
		Education leve	el		
Illiterate	50 (16.45)	0(0.00)		4(8.00)	0.72
Basic	71 (23.36)	7(9.86)		10(14.08)	
Primary	47 (15.46)	5(10.64)	0.07	8(17.02)	
Secondary	93 (30.59)	4(4.30)		13(13.98)	
University	43 (14.14)	1(2.33)		7(16.28)	
		Occupation			
House wife	292(96.05)	17(5.82)	0.39	41(14.04)	0.57
Employee	12 (3.95)	0(0.00)		1(8.33)	0.57

ÔbstetricalNo.(%)No.(%)P. ValueNo.(%)P. ValueFirst135 (44.1)6(4.44)14(1.25.9)17(12.59)16(5.4)Second93 (30.59)6(6.45)0.7413(13.98)0.81Third76 (25.00)6(5.68)0.7412(15.79)10(11.79)Third76 (25.00)16(5.68)14 (14.29)10(0.00)180 (59.21)11(6.11)28(15.65)0.00One to four180 (59.21)111(6.11)0.69928(15.65)0.0028(15.65)0.00>four26 (8.55)2 (7.69)0.2630(0.00)28(15.65)0.000.09No288 (94.74)17(5.90)0.230(0.00)42(14.58)0.09No288 (94.74)12(5.85)0.0711(11.11)0.43No205 (67.43)12(5.85)11(11.11)0.43No205 (67.43)12(5.85)31(15.12)0.67Yes24 (7.89)14(17)0.7538(13.57)0.67Yes28 (92.11)16(5.71)113(15.12)0.09No28 (92.11)16(5.71)113(15.7)0.01Yes28 (92.13)0(0.00)13(15.7)13(13.67)0.01Yes28 (92.11)0(0.00)13(15.7)13(13.67)0.01Yes28 (92.11)0(0.00)13(15.7)13(13.67)0.01No29 (90.79)17(6.16)13(13.67)0.01Yes6 (1.97)0(0.00)0.5413(13.67)0.01 <t< th=""><th rowspan="2">Reproductive & Obstetrical</th><th>Participants</th><th colspan="2">IgG Positive IgM</th><th>IgM Positi</th><th colspan="2">gM Positive</th></t<>	Reproductive & Obstetrical	Participants	IgG Positive IgM		IgM Positi	gM Positive	
First 135 (44.1) 6(4.44) 17(12.59) 13(13.98) 0.81 Second 93 (30.59) 6(6.45) 0.74 13(13.98) 0.81 Third 76 (25.00) 5(6.58) 12(15.79) 0.81 Third 76 (25.00) 5(6.58) 12(15.79) 0.81 None 98 (32.24) 4 (4.08) $A = 0.09$ 28(15.56) 0.09 often to four 180 (59.21) 111(6.11) 0.69 28(15.56) 0.09 >four 26 (8.55) 2 (7.69) 0 (0.00) 0 (0.00) $A = 0.09$ >four 26 (8.57) 2 (7.69) 0.32 0 (0.00) $A = 0.09$ No 288 (9.474) 17 (5.90) $A = 0.77$ 11 (11.11) $A = 0.94$ No 205 (67.43) 12 (5.85) 0.77 11 (11.11) $A = 0.47$ No 205 (67.43) 12 (5.85) $A = 0.77$ 31 (15.12) $A = 0.47$ No 280 (92.11) 16 (5.71) $A = 0.76$ 38 (13.57) $A = 0.67$		No. (%)	No. (%)	P- Value	No. (%)	P- Value	
Second 93 (30.59) 6(6.45) 0.74 13(13.98) 0.81 Third 76 (25.00) 5(6.58) 12(15.79) 12(15.79) None 98 (32.24) 4 (4.08) 14 (14.29) 0.09 One to four 130 (59.21) 111(6.11) 0.69 28(15.56) 0.09 >four 26 (8.55) 2 (7.69) 0 (0.00) 0 (0.00) 0.09 >four 26 (8.55) 2 (7.69) 0 (0.00) 0.09 0.09 No 288 (94.74) 17 (5.90) 0.32 0 (0.00) 0.09 No 288 (94.74) 17 (5.90) 0.77 11 (11.11) 0.09 No 288 (94.74) 12 (5.85) 0.77 11 (11.11) 0.34 Ves 99 (32.57) 5 (5.05) 0.77 11 (11.11) 0.34 No 205 (67.43) 12 (5.85) 0.77 13 (15.12) 0.67 Yes 24 (7.89) 1 (4.17) 0.75 38 (13.57) 0.67 No 280 (92.1) 16 (5.7			Trimester				
Third 76 (25.00) 5 (6.58) 12 (15.79) Parity 12 (15.79) 12 (15.79) None 98 (32.24) 4 (4.08) 14 (14.29) 0.09 One to four 180 (59.21) 111 (6.11) 0.69 28 (15.56) 0.09 > four 26 (8.55) 2 (7.69) 0 (0.00) 0 (0.00) 0.09 > four 26 (8.57) 2 (7.69) 0.32 0 (0.00) 0.09 No 288 (94.74) 17 (5.90) 0.32 0 (0.00) 0.09 No 288 (94.74) 17 (5.90) 0.32 0 (0.00) 0.09 No 288 (94.74) 17 (5.90) 0.32 0 (0.00) 0.09 No 288 (94.74) 17 (5.90) 0.77 11 (11.11) 0.34 Yes 9 (32.57) 5 (5.05) 0.77 31 (15.12) 0.34 No 205 (67.43) 12 (5.85) 0.75 38 (13.57) 0.67 No 280 (92.11) 16 (5.71) 0.75 38 (13.57) 0.67	First	135 (44.41)	6(4.44)		17(12.59)		
Parity Parity Parity None 98 (32.24) 4 (4.08) 4 (4.08) 14 (14.29) 0.09 One to four 180 (59.21) 11(6.11) 0.69 $28(15.56)$ 0.09 > four 26 (8.55) 2 (7.69) 0.69 $0(0.00)$ 0.09 > four 26 (8.55) 2 (7.69) 0.00 0.09 0.00 No 288 (94.74) 17(5.90) 0.32 $0(0.00)$ 0.09 No 288 (94.74) 17(5.90) 0.32 $0(0.00)$ 0.09 No 288 (94.74) 17(5.90) 0.77 $11(11.11)$ 0.34 Yes 99(32.57) 5(5.05) 0.77 $11(11.11)$ 0.34 No 205(67.43) 12(5.85) 0.75 $38(13.57)$ 0.67 Yes 24 (7.89) 1(4.17) 0.75 $4(16.67)$ 0.67 No 280 (92.11) 16(5.71) 0.18 $1(3.57)$ 0.09 No 28 (9.21) 0(0	Second	93 (30.59)	6(6.45)	0.74	13(13.98)	0.81	
None 98 (32.24) 4 (4.08) 4 (4.08) 14 (14.29) 0.09 One to four 180 (59.21) 11 (6.11) 0.69 28 (15.56) 0.09 > four 26 (8.55) 2 (7.69) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) > four 26 (8.55) 2 (7.69) 0.32 0 (0.00) 0 (0.00) Yes 16 (5.26) 0 (0.00) 0.32 0 (0.00) 42 (14.58) 0.09 No 288 (94.74) 17 (5.90) 0.32 4 (10.60) 42 (14.58) 0.09 No 288 (94.74) 17 (5.90) 0.77 11 (11.11) 0.34 No 205 (67.43) 12 (5.85) 0.77 11 (11.11) 0.34 No 205 (67.43) 12 (5.85) 0.75 38 (13.57) 0.67 Yes 24 (7.89) 1 (4.17) 0.75 38 (13.57) 0.67 No 280 (92.11) 16 (5.71) 0.18 1 (3.57) 0.09 No 28 (9.21) 0 (0.00) 0.18	Third	76 (25.00)	5(6.58)		12(15.79)		
$ \begin{array}{c c c c c c } \hline \begin{tabular}{ c c c c } \hline \hline \end{tabular} \\ \hline \hline \end{tabular} \\ \hline \end{tabular} \\$		Parity			·		
>four 26 (8.55) 2 (7.69) 0 (0.00) 0 (0.00) Preterm deliveries Preterm deliveries 0 (0.00) 0.32 0 (0.00) 0.09 No 288 (94.74) 17 (5.90) 0.32 0 (0.00) 0.09 No 288 (94.74) 17 (5.90) 0.32 42 (14.58) 0.09 Yes 99 (32.57) 5 (5.05) 0.77 11 (11.11) 0.34 No 205 (67.43) 12 (5.85) 0.77 31 (15.12) 0.34 Yes 99 (32.57) 5 (5.05) 0.77 38 (13.57) 0.34 No 205 (67.43) 12 (5.85) 0.75 38 (13.57) 0.67 Yes 24 (7.89) 1 (4.17) 0.75 4 (16.67) 0.67 No 280 (92.11) 16 (5.71) 0.75 38 (13.57) 0.67 No 28 (9.21) 0 (0.00) 0.18 1 (3.57) 0.99 No 27 (6 (9.79) 17 (6.16) 0.18 1 (16.67) 0.93 Yes 6 (1.97)<	None	98 (32.24)	4 (4.08)		14 (14.29)		
Preterm deliveries Preterm deliveries Yes 16 (5.26) 0(0.00) 0.32 0(0.00) 0.09 No 288 (94.74) 17(5.90) 0.32 42(14.58) 0.09 Yes 99(32.57) 5(5.05) 0.77 11(11.11) 0.34 No 205(67.43) 12(5.85) 0.77 11(11.11) 0.34 No 205(67.43) 12(5.85) 0.77 11(16.67) 0.34 Yes 24 (7.89) 1(4.17) 0.75 4(16.67) 0.67 No 280 (92.11) 16(5.71) 0.75 4(16.67) 0.67 No 280 (92.11) 16(5.71) 0.75 4(16.67) 0.67 No 280 (92.11) 16(5.71) 0.18 1(3.57) 0.09 No 28 (9.21) 0(0.00) 0.18 1(3.57) 0.09 No 276 (90.79) 17(6.16) 0.18 1(16.67) 0.83	One to four	180 (59.21)	11(6.11)	0.69	28(15.56)	0.09	
Yes 16 (5.26) 0(0.00) 0.32 0(0.00) 0.09 No 288 (94.74) 17(5.90) 0.32 $42(14.58)$ 0.09 Yes 99(32.57) 5(5.05) 0.77 $11(11.11)$ 0.34 No 205(67.43) 12(5.85) 0.77 $11(11.11)$ 0.34 Yes 24 (7.89) 1(4.17) 0.75 $4(16.67)$ 0.67 Yes 24 (7.89) 1(4.17) 0.75 $4(16.67)$ 0.67 No 280 (92.11) 16(5.71) 0.75 $4(16.67)$ 0.67 No 280 (92.12) 10(0.00) 0.18 $1(3.57)$ 0.09 No 276 (90.79) 17(6.16) 0.18 $1(3.57)$ 0.09 No 276 (90.79) 17(6.16) 0.18 $1(14.86)$ 0.09 No 276 (90.79) 10(0.00) 0.54 $1(16.67)$ 0.83	>four	26 (8.55)	2 (7.69)	_	0 (0.00)		
No 288 (94.74) 17(5.90) 0.32 $(C - J)$ 0.09 No 288 (94.74) 17(5.90) 0.32 $42(14.58)$ 0.09 Yes 99(32.57) 5(5.05) 0.77 11(11.11) 0.34 No 205(67.43) 12(5.85) 0.77 11(11.11) 0.34 Ves 24 (7.89) 1(4.17) 0.75 4(16.67) 0.67 No 280 (92.11) 16(5.71) 0.75 38(13.57) 0.67 No 280 (92.11) 16(5.71) 0.18 1(3.57) 0.09 Yes 28 (9.21) 0(0.00) 0.18 1(3.57) 0.09 No 276 (90.79) 17(6.16) 0.18 1(3.57) 0.09 No 276 (90.79) 17(6.16) 0.54 1(16.67) 0.83			Preterm delive	ries			
No 288 (94.74) 17(5.90) 42(14.58) History of aborton Yes 99(32.57) 5(5.05) -0.77 11(11.11) -0.34 No 205(67.43) 12(5.85) -0.77 31(15.12) -0.34 Yes 24 (7.89) 1(4.17) -0.75 4(16.67) -0.67 No 280 (92.11) 16(5.71) -0.75 38(13.57) -0.67 No 280 (92.11) 16(5.71) -0.18 1(13.57) -0.67 No 28 (9.21) 0(0.00) -0.18 1(3.57) -0.09 No 276 (90.79) 17(6.16) -0.18 1(13.67) -0.09 No 276 (90.79) 17(6.16) -0.54 1(16.67) -0.83	Yes	16 (5.26)	0(0.00)	0.32	0(0.00)	0.00	
Yes 99(32.57) 5(5.05) 0.77 11(11.1) 0.34 No 205(67.43) 12(5.85) 0.77 31(15.12) 0.34 History of cesarean sections Yes 24 (7.89) 1(4.17) 0.75 4(16.67) 0.67 No 280 (92.11) 16(5.71) 0.75 4(16.67) 0.67 No 280 (92.11) 16(5.71) 0.75 11(3.57) 0.67 Yes 28 (9.21) 0(0.00) 0.18 1(3.57) 0.09 No 276 (90.79) 17(6.16) 0.18 1(14.86) 0.09 Yes 6 (1.97) 0(0.00) 0.54 1(16.67) 0.83	No	288 (94.74)	17(5.90)		42(14.58)	0.09	
No 205(67.43) 12(5.85) 0.77 $31(15.12)$ 0.34 Wes 24 (7.89) 1(4.17) 0.75 4(16.67) 0.67 No 280 (92.11) 16(5.71) 0.75 4(16.67) 0.67 Wes 28 (92.11) 16(5.71) 0.75 4(16.67) 0.67 No 280 (92.11) 16(5.71) 0.18 1(3.57) 0.09 Yes 28 (9.21) 0(0.00) 0.18 1(3.57) 0.09 No 276 (90.79) 17(6.16) 0.18 1(16.67) 0.09 Wes 6 (1.97) 0(0.00) 0.54 1(16.67) 0.83			History of abor	tion			
No 205(67.43) 12(5.85) 31(15.12) History of cesarean sections Yes 24 (7.89) 1(4.17) 0.75 4(16.67) 0.67 No 280 (92.11) 16(5.71) 0.75 38(13.57) 0.67 Yes 28 (9.21) 0(0.00) 0.18 1(3.57) 0.09 No 276 (90.79) 17(6.16) 0.18 1(14.86) 0.09 No 26 (1.97) 0(0.00) 0.54 1(16.67) 0.83	Yes	99(32.57)	5(5.05)	0.77	11(11.11)	0.04	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	No	205(67.43)	12(5.85)		31(15.12)	0.34	
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$			History of cesarean	sections			
No 280 (92.11) 16(5.71) 38(13.57) History of stillbirths Yes 28 (9.21) 0(0.00) 0.18 1(3.57) 0.09 No 276 (90.79) 17(6.16) 0.18 1(14.86) 0.09 Malformed children Yes 6 (1.97) 0(0.00) 0.54 1(16.67) 0.83	Yes	24 (7.89)	1(4.17)	0.55	4(16.67)	0.67	
$\begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	No	280 (92.11)	16(5.71)	- 0.75	38(13.57)	0.67	
No 276 (90.79) 17(6.16) 0.18 41(14.86) 0.09 Malformed children Malformed children 0.09		1	History of stillbi	irths	1		
No 276 (90.79) 17(6.16) 41(14.86) Malformed children Yes 6 (1.97) 0(0.00) 1(16.67) 0.83	Yes	28 (9.21)	0(0.00)	0.18	1(3.57)		
Yes 6 (1.97) 0(0.00) 1(16.67) 0.83	No	276 (90.79)	17(6.16)		41(14.86)	0.09	
0.54 0.83			Malformed child	dren		!	
	Yes	6 (1.97)	0(0.00)	0.54	1(16.67)	0.02	
	No	298 (98.03)	17(5.7)	0.54	41(13.76)	0.83	

Table 2: Distributions of brucella IgM and IgG antibodies among pregnant women according to their reproductive and obstetrical characteristics.

Table 3: Seroprevalence of brucella IgM and IgG antibodies among pregnant women according to risk factors.

Risk Factors	Participants	IgG Positive		IgM Positive	
	No. (%)	No. (%)	P- Value	No. (%)	P- Value
		Animals at ho	me		
Yes	107 (35.20)	6(5.61)	0.00	11 (10.28)	0.19
No	197 (64.80)	11(5.58)	0.99	31 (15.74)	
	Milking animals				
Yes	36 (11.84)	2(5.56)	0.99	2(5.56)	0.12
No	268(88.16)	15(5.60)		40(14.93)	
	· · · · · · · · · · · · · · · · · · ·	Contact with animal'	s newborn		·

Yes	27 (8.88)	1(3.70)	0.65	1(3.70)	- 0.11
No	277 (91.12)	16(5.78)		41(14.80)	
		Touch a fresh	meat		
Yes	283 (93.09)	15(5.30)	0.41	37(13.07)	0.17
No	21(6.91)	2(9.52)	0.41	5(23.81)	0.17
		Fresh mil	k		
Yes	91 (29.9)	8(47.1)	0.11	10(23.8)	0.25
No	213 (70.1)	9(52.9)	0.11	32(76.2)	0.35
		Raw liver and	spleen		
Yes	8 (2.63)	0(0.00)	0.40	0(0.00)	0.25
No	296 (97.37)	17(5.74)	0.48	42(14.19)	
		Yogurt		·	
Yes	178 (58.55)	10(5.62)	0.00	21(11.80)	0.22
No	126 (41.45)	7(5.56)	0.98	21(16.67)	
		Is there anyone at hon	ne as butcher?	·	
Yes	8 (2.63)	1(12.50)	0.20	1(12.50)	0.91
No	296 (97.37)	16(5.41)	0.39	41(13.58)	
		Is there anyone at hor	ne as farmer?		
Yes	36 (11.84)	0(0.00)	0.40	2(5.56)	0.13
No	268 (88.16)	17(6.34)	0.12	40(14.93)	
	l	s there anyone at home a	s microbiologist?		
Yes	7 (2.30)	0(0.00)	0.51	0(0.0)	0.28
No	297 (97.70)	17(5.72)		42(14.14)	
		Is there anyone at home	as veterinarian?		
Yes	2 (0.66)	0(0.00)	0.70	0(0.0)	0.54
No	302 (99.34)	17(5.63)	0.73	42(13.91)	0.56

Table 4: Seroprevalence of brucella IgM and IgG antibodies among pregnant women according to clinical symptoms associated with brucella infection.

Clinical Symptoms	Participants	IgG Positive		IgM Positive	
	No. (%)	No. (%)	P- Value	No. (%)	P- Value
		Fever			
Yes	140 (46.05)	7(5.00)	0.68	18(12.86)	0.65
No	164 (53.95)	10(6.10)		24(14.63)	
	Undulant fever				
Yes	130 (42.76)	5(3.85)	0.25	11(8.46)	0.02*
No	174 (57.24)	12(6.90)		31(17.82)	0.02*
		Anorexia			

Yes	164 (53.95)	10(6.10)	0.60	21(12.80)	0.50
No	140 (46.05)	7(5.00)	0.68	21(15.00)	- 0.58
		Weightlo	SS		L.
Yes	120 (39.47)	5(4.17)	0.00	11(9.17)	0.07
No	184 (60.53)	12(6.52)	0.38	31(16.85)	0.06
		Pain musc	les		
Yes	176 (57.8)	13(76.4)	0.11	28(66.6)	0.00
No	128 (42.11)	4(23.5)	0.11	14(33.3)	0.22
		Pain bac	k		
Yes	234 (76.97)	13(5.56)	0.07	35(14.96)	0.20
No	70 (23.03)	4(5.71)	0.96	7(10.00)	0.29
		Pain head b	back		
Yes	131 (43.09)	9(6.87)	0.00	19(14.50)	0.54
No	173 (56.91)	8(4.62)	0.39	23(54.7)	0.76
		Coldnes	s		
Yes	240 (78.95)	15(6.25)	0.00	33(13.75)	0.05
No	64 (21.05)	2(3.13)	0.33	9(14.06)	0.95
		Headach	e		
Yes	165 (54.28)	14(8.48)	0.01*	28(16.97)	0.00
No	139 (45.72)	3(2.16)	- 0.01*	14(10.07)	0.08
		Fatigue			
Yes	207 (68.09)	11(5.31)	0.54	29(14.01)	0.00
No	97 (31.91)	6(6.19)	0.76	13(13.40)	0.88
		Sweaty			
Yes	85 (27.96)	2(2.35)	0.12	9(10.59)	0.21
No	219 (72.04)	15(6.85)	0.12	33(15.07)	0.31
		Cold			
Yes	153 (50.33)	9(5.88)	0.82	22(14.38)	0.77
No	151 (49.67)	8(5.30)	0.82	20(13.25)	0.77
		Deliriur	n		
Yes	38 (12.50)	0(0.00)	0.10	2(5.26)	0.10
No	266 (87.50)	17(6.39)	0.12	40(15.04)	0.10

Discussion

This data is the first published data on the Seroprevalence of brucellosis among pregnant women in Yemen. Overly, the prevalence of brucella antibodies among pregnant women was 45 (15%), Our findings were in close agreement with the previous study in Egypt (12.2%) among pregnant women [22] and in Rwanda 25% among women who suffered from abortions and stillbirth [23]. While our findings were higher than the previous study among pregnant women reported in Iran (6.2%) [24], Pakistan (5.8%) [20], Saudi Arabia (3.5%) [25], and Turkey (3.7%) [26]. In this current study the seroprevalence of brucella

IgG antibodies were 5.59% (17/304). The development of IgG antibody is an effort which is made by the immune system to help neutralize brucella. This antibody prolongs life and confers immunity against reinfection. So, it is correct to consider pregnant women who had IgG antibodies are immune.

A clearer picture was seen when the seroprevalence of IgM antibody to brucella was also considered. A prevalence of 13.82% for IgM antibody among pregnant women was obtained. Significantly, 4.6% of these subjects also had IgG antibody, suggesting that either reinfection or resolving primary infection and that they were not actually immune as concluded earlier, but were still in the recovery stage. In this present study, most of pregnant women were in their first trimester which found that women in the first trimester were (4.44% and 12.59% for brucella IgG and IgM respectively). Vilchez et al. [27] found higher rates of abortion in the first trimester while, Khan et al. [28] found that the spontaneous abortion usually occurs in the second trimester.

In this current study, there is a significant association between brucella IgM seropositivity and urban area residence. Human brucellosis is found to have significant presence in rural/nomadic communities where people live in close association with animals [29]. The reported incidence of human brucellosis in endemic disease areas varies widely, <0.01 to >200 per 100000 population. Brucellosis is still a main public health problem in developing countries. Endemicity in this region results from the persistence of domestic animals as reservoirs. People from third to fifth decades of life are most commonly affected [30]. In urban areas, the main sources of brucella infection are slaughterhouses, dairies, laboratories conducting investigations handling live brucella cultures and veterinary institutions [31]. Control by veterinarians of the disease in cattle, dogs, sheep, goats has substantially controlled brucellosis in humans. Mainly, the infection by Brucella abortus and Brucella suis are seen in people engaged in some aspects of the live-stock industries, whereas Brucella melitensis is primarily food borne and is associated with consumption of unpasteurized milk and milk products [30].

The reproductive characteristics which has been studied in this research were not statistically significant with the presence of IgM or IgG antibodies. There were no previous studies which considered the association between the listed reproductive characteristics and risk of brucella infection. However, spontaneous abortion is defined as loss of pregnancy without outside intervention before 20 weeks of gestation. Up to 20% of the recognized pregnancies will end in spontaneous abortions [32]. Infection of conceptus is one of the causes of abortion. Although brucellosis can result in human abortion, it is debated whether it is more frequent due to brucellosis than due to other bacterial infections [30]. In our study, the result suggests that all reproductive characteristics studied are not significant predisposing factors to brucella infection or immunity. Our result was similar to study carried out in Jordon by Abo-Shehada and Abu-Halaweh [33] who found that there was no statistically significant difference between history of miscarriage and brucella infection. While, the results of study by (Elshamy and Ahmed [22] reported that there was a statistically significant difference in the

incidence of abortion in pregnant women with brucella antibodies titre of more than 1/160 compared to those women with titre of less than 1/160 (44.1 versus 19.4%, respectively, *P* value 0.03).

There was no statistically significant association between all possible risk factors and brucella infection. Although, many people in Yemen keep livestock in and around the family home with family members tending goats, sheep and sometimes cattle. They live in close proximity to their livestock which may be kept in the lower floor of the home, consume untreated milk and make laban (buttermilk) using unhygienic methods. Milk and laban are sold to the consumer directly or through groceries in cities and towns. In previous studies conducted in Yemen on human brucellosis showed that significant risk factors for brucella infection related to farmer, shepherd, as occupation, and microbiologist [34]. But, the highly significant risk factors for infection were related to be associated with ownership of livestock animals [19], contact with clearing viscera of animals and placental membrane, [18] and direct contact with their products (Handling new born, milking, and animal slaughter) and indirect contact with livestock (drinking unpasteurized milk [18,19,34], drinking laban [19,34], ingestion of local chees, raw liver and raw spleen) [19]. Brucellosis is sufficiently common in Yemen that specific public health measures are needed to combat this debilitating disease but these measures may need to be targeted at specific routes of infection among defined groups.

Many of the common clinical symptoms associated with brucella infection were observed in the pregnant women. Which included fever, headaches, lack of appetite, weight loss, fatigue, malaise, chills, sweats, myalgia, and arthralgia [8-11]. In this findings, there were significant association with headache and undulant fever and the seropositivity for brucella IgG and IgM antibodies respectively. Most of pregnant women in this research made complaints of delirium. Few of these women were, positive for brucella (IgM antibody), suggesting that the delirium was due to other factors. The overall clinical picture of human brucellosis likewise was reported by other researchers in this geographical area. Another previous study in southern part of Yemen, [35] studied 235 cases of human brucellosis in Sana'a city giving male: female ratio of 1.3: 1% respectively. This present study suggest that male and female exposure to the risk of brucella infection is about the same, and that the activities associated with exposure are performed by both sexes or that they are exposed to the same reservoir of infected animals but at different point in the cycle of contact.

Limitations of the Study

Polymerase Chain Reaction (PCR) test of the bacterial DNA isolation was not used due to financial constraints.

Conclusion

The overall seroprevalence of brucella antibodies was high. This is suggesting that a sustained infection in the Yemeni population and indicating endemicity. Adoption of brucella screening into the antenatal profile tests is recommended for early

detection and treatment. Advance study intended to compare all provinces in the country with brucella seroprevalence in order to get comprehensive information of the problem is recommended.

Acknowledgement

We acknowledge contribution of all women in science, who support and contribute in this study. This research work was supported Department of Biology, Faculty of Science, Sana'a University, Sana'a, Yemen. We are also grateful to Al- Thobhani Modern Medical Laboratory, Sana'a, Yemen for their cooperation.

References

- 1. Corbel M, Elberg S, Cosivi O (2006) Brucellosis in humans and animals World Health Organization. Geneva Open URL.
- 2. Grimont F, Verger JM, Cornelis P (1992) Molecular typing of brucella with cloned DNA probes. Res Microbiol 143(1): 55-65.
- Moreno E, Stackebrandt E, Dorsch M, Wolters J, Busch M, et al. (1990) Brucella abortus 16S rRNA and lipid A reveal a phylogenetic relationship with members of the alpha-2 subdivision of the class Proteobacteria. J Bacteriol 172(7): 3569-3576.
- Boschiroli ML, Foulongne V, O'Callaghan D (2001) Brucellosis a worldwide zoonosis. Curr Opin Microbiol 4(1): 58-64.
- Chen S, Zhang H, Liu X, Wang W, Hou S, et al. (2014) Increasing threat of brucellosis to low-risk persons in urban settings, China. Emerg Infect Dis 20(1): 126-130.
- Mesner O, Riesenberg K, Biliar N, Borstein E, Bouhnik L, et al. (2007) The many faces of human-to-human transmission of brucellosis: congenital infection and outbreak of nosocomial disease related to an unrecognized clinical case. Clin Infect Dis 45(12): 135-140.
- Peker N, Volkan T, Mete E, Ozgur Y (2011) Brucellosis in adolescent pregnancy-case report and review of literature. Ginekol Pol 82(3): 226-229.
- Ali S, Ali Q, Neubauer H, Melzer F, Elschner M, et al. (2013) Seroprevalence and risk factors associated with brucellosis as a professional hazard in Pakistan. Foodborne Pathog Dis 10(6): 500-505.
- Dames S, Tonnerre C, Saint S, Jones SR (2005) Clinical problem solving. Don't know much about history. N Engl J Med 352: 2338-2342.
- Dean AS, Crump L, Greter, H, Hattendorf J, Schelling E, et al. (2012) Clinical manifestations of human brucellosis: a systematic review and meta-analysis. PLoS Negl Trop Dis 6(12): 10-12.
- Young EJ (1989) Clinical manifestations of human brucellosis. CRC press, Boca Raton 97: 126.
- 12. Eyre JWH (1908) Melitensis septicemia. Lancet 5: 1747-1752.
- Seoud M, Saade G, Awar G, Uwaydah M (1991) Brucellosis in pregnancy. J Reprod Med 36: 441-445.
- 14. Young EJ (1983) Human brucellosis. Rev Infect Dis 5(5): 821-842.
- Poole PM, Whitehouse DB, Gilchrist MM (1972) A case of abortion consequent upon infection with Brucella abortus biotype 2. J Clinl Pathol 25(10): 882-884.
- 16. (2006) Brucellosis in humans and animals. WHO.
- Al-Arnoot S, Abdullah QYM, Alkhyat SH, Almahbashi AA, Al-Nowihi M (2017) Human and Animal Brucellosis in Yemen. J Hum Virol

Retrovirol 5(4): 00162.

- Nasher AAM (2006) Brucellosis in human associated with animals in Sana'a-Yemen and in laboratory prepared antigen for antibody detected. Msc thesis. Department of Microbiology, Faculty of Medicine and Health Sciences, Sana'a University, Yemen.
- Al-Haddad AM, Al-Madhagi A, Talab AA, Al-Shamahy H (2013) Prevalence of human brucellosis in three selected areas at Al-Dhala'a Governorate, Yemen. Msc thesis. Department of Microbiology, Faculty of Medicine and Health Sciences, Sana'a University, Yemen. Faculty of Science Bulletin, Sana'a University, 25: 61-71.
- Ali S, Akhter S, Neubauer H, Scherag A, Kesselmeier M, et al. (2016) Brucellosis in pregnant women from Pakistan: an observational study. BMC Infect Dis 16(1): 468.
- Saleh NAA (2000) Seroprevalence of brucellosis among slaughterhouse workers in the Republic of Yemen. Msc thesis. Department of Microbiology, Faculty of Medicine and Health Sciences, Sana'a University, Yemen.
- 22. Elshamy M, Ahmed AI (2008) The effects of maternal brucellosis on pregnancy outcome. J Infect Dev Ctries 2(3): 230-234.
- Rujeni N, Mbanzamihigo L (2014) Prevalence of brucellosis among women presenting with abortion/stillbirth in Huye, Rwanda. Journal of Tropical Medicine 2014.
- Salari MH, Khalil MB, Hassanpour GR (2003) Selected epidemiologic features of human brucellosis in Yazd, Islamiv Republic of Iran (1993-1998). East Mediterr Health J 9: 5-6.
- 25. Sharif A, Reyes Z, Thomassen P (1990) Screening for brucellosis in pregnant women. J Trop Med Hyg 93(1): 42-43.
- Fevziye C, M Nacer N, Koc AN, Selma G, Lay T (2005) Prevalence of brucellosis in the rural areas of Kayseri, Central Anatolia, Turkey. Turk J Med Sci 35: 121-126.
- Vilchez G, Espinoza M, D'Onadio G, Saona P, Gotuzzo E (2015) Brucellosis in pregnancy: clinical aspects and obstetric outcomes. Int J Infec Dis 38: 95-100.
- Khan MY, Mah MW, Memish ZA (2001) Brucellosis in pregnant women. Brucellosis in pregnant women. Clin Infect Dis 32(8): 1172-1177.
- 29. Boschiroli M-L, Foulongne V, O'Callaghan D (2001) Brucellosis: a worldwide zoonosis. Curr Opin Microbiol 4(1): 58-64.
- Puri M, Patel N, Gaikwad V, Despande H, Pandey P (2015) A Study of Prevalence of Brucellosis in Cases of Spontaneous Abortions. RJPBCS 6(3): 312-320.
- Castaneda MR (1961) Laboratory diagnosis of brucellosis in man. Bull World Health Organ 24(1): 73-84.
- Griebel CP, Halvorsen J, Golemon TB, Day AA (2005) Management of spontaneous abortion. Am Fam Physician 72(7): 1243-1250.
- Abo-Shehada MN, Abu-Halaweh M (2011) Seroprevalence of Brucella species among women with miscarriage in Jordan. East Mediterr Health J 17(11): 871-874.
- Al- Shamahy H, Whitty CJM, Wright SG (2000) Risk factors for human brucellosis in Yemen: a case control study. Epidemiol Infect 125(2): 309-313.
- Al- Shamahy H, Wright SG (2001) A study of 235 cases of human brucellosis in Sana'a, Republic of Yemen. East Mediterr Health J 7(1-2): 238-246.